ArticleFrontiers in cell and developmental biology2026
CLK1 is a potential tumor suppressor for NSCLC by regulating cell proliferation and immune infiltration.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the malignancy with the highest global incidence and mortality. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of cases and is characterized by complex drug resistance and poor prognosis. While CLK1 has been implicated in Alzheimer's disease, pancreatic cancer proliferation, and chemotherapy resistance in lymphoma, its role in NSCLC, particularly in the context of tumor immune infiltration, remains unexplored. Methods: CLK1 expression and prognostic significance were analyzed across cancers and in LUAD using bioinformatics platforms (GEPIA, UALCAN). Functional enrichment analyses (GSEA, KEGG, GO) elucidated associated pathways and immune correlations. Drug sensitivity screening (GDSC, CTRP, CellMiner) identified potential compounds targeting CLK1-high tumors. Experimental validation was performed using clinical samples from NSCLC patients (n = 12) and Results: Contrary to its oncogenic role in other cancers, CLK1 acts as a tumor suppressor in NSCLC. High CLK1 expression correlated with prolonged survival, suppressed cell cycle and metabolism pathways, and enhanced anti-tumor immunity-particularly CD4 Conclusion: Our findings demonstrate that CLK1 functions as a tumor suppressor gene in NSCLC, inhibiting proliferation and promoting immune infiltration. It also correlates positively with sensitivity to multiple chemotherapeutic agents. Thus, CLK1 may serve as a novel prognostic biomarker and a potential target for combination therapy in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.